Cargando…

1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway

Gastric ulcer (GU) is a main threat to public health. 1-Deoxynojirimycin (DNJ) has antioxidant and anti-inflammatory properties and may prevent GU but related mechanism remains unclear. DNJ was extracted from the supernatants of Bacillus subtilis by using ethanol and purified by using CM-Sepharose c...

Descripción completa

Detalles Bibliográficos
Autores principales: Piao, Xuehua, Li, Shuangdi, Sui, Xiaodan, Guo, Lianyi, Liu, Xingmei, Li, Hongmei, Gao, Leming, Cai, Shusheng, Li, Yanrong, Wang, Tingting, Liu, Baohai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917448/
https://www.ncbi.nlm.nih.gov/pubmed/29725297
http://dx.doi.org/10.3389/fphar.2018.00372
_version_ 1783317212007759872
author Piao, Xuehua
Li, Shuangdi
Sui, Xiaodan
Guo, Lianyi
Liu, Xingmei
Li, Hongmei
Gao, Leming
Cai, Shusheng
Li, Yanrong
Wang, Tingting
Liu, Baohai
author_facet Piao, Xuehua
Li, Shuangdi
Sui, Xiaodan
Guo, Lianyi
Liu, Xingmei
Li, Hongmei
Gao, Leming
Cai, Shusheng
Li, Yanrong
Wang, Tingting
Liu, Baohai
author_sort Piao, Xuehua
collection PubMed
description Gastric ulcer (GU) is a main threat to public health. 1-Deoxynojirimycin (DNJ) has antioxidant and anti-inflammatory properties and may prevent GU but related mechanism remains unclear. DNJ was extracted from the supernatants of Bacillus subtilis by using ethanol and purified by using CM-Sepharose chromatography. A GU mouse model was induced by indomethacin. The functional role of DNJ in GU mice was explored by measuring the main molecules in the NF-KappaB pathway. After the model establishment, 40 GU mice were evenly assigned into five categories: IG (received vehicle control), LG (10 μg DNJ daily), MG (20 μg DNJ daily), HG (40 μg DNJ daily), and RG (0.5 mg ranitidine daily). Meanwhile, eight healthy mice were assigned as a control group (CG). After 1-month therapy, weight and gastric volume were investigated. The levels of serum inflammatory cytokines (IL-6 and TNF-α), antioxidant indices [superoxide dismutase (SOD), catalase (CAT), and reduced glutathione (GSH)], and oxidant biomarker malondialdehyde (MDA) were examined via ELISA. Meanwhile, inflammatory cytokine (IL-6 and TNF-α) levels, and key molecules (NF-κB p65), cyclooxygenase 1 (COX-1 and COX2) involved in NF-κB pathway, were analyzed by using Western Blot. COX-1 and COX-2 levels were further measured by immunohistochemistry. The effects of DNJ on gastric functions were explored by measuring the changes of Motilin (MOT), Substance P (SP), Somatostatin (SS), and Vasoactive intestinal peptide (VIP) in GU mouse models with ELISA Kits. The results indicated that DNJ prevented indomethacin-caused increase of gastric volume. DNJ improved histopathology of GU mice when compared with the mice from IG group (P < 0.05). DNJ consumption decreased the levels of IL-6 and TNF-α (P < 0.05). DNJ increased antioxidant indices of GU mice by improving the activities of SOD, CAT and reduced GSH, and reduced MDA levels (P < 0.05). DNJ increased the levels of prostaglandin E2, COX-1, COX2, and reduced the levels of and NF-κB p65 (P < 0.05). DNJ showed protection for gastric functions of GU mice by reducing the levels of MOT and SP, and increasing the levels of SS and VIP. DNJ treatment inactivates NF-κB signaling pathway, and increases anti-ulceration ability of the models.
format Online
Article
Text
id pubmed-5917448
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-59174482018-05-03 1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway Piao, Xuehua Li, Shuangdi Sui, Xiaodan Guo, Lianyi Liu, Xingmei Li, Hongmei Gao, Leming Cai, Shusheng Li, Yanrong Wang, Tingting Liu, Baohai Front Pharmacol Pharmacology Gastric ulcer (GU) is a main threat to public health. 1-Deoxynojirimycin (DNJ) has antioxidant and anti-inflammatory properties and may prevent GU but related mechanism remains unclear. DNJ was extracted from the supernatants of Bacillus subtilis by using ethanol and purified by using CM-Sepharose chromatography. A GU mouse model was induced by indomethacin. The functional role of DNJ in GU mice was explored by measuring the main molecules in the NF-KappaB pathway. After the model establishment, 40 GU mice were evenly assigned into five categories: IG (received vehicle control), LG (10 μg DNJ daily), MG (20 μg DNJ daily), HG (40 μg DNJ daily), and RG (0.5 mg ranitidine daily). Meanwhile, eight healthy mice were assigned as a control group (CG). After 1-month therapy, weight and gastric volume were investigated. The levels of serum inflammatory cytokines (IL-6 and TNF-α), antioxidant indices [superoxide dismutase (SOD), catalase (CAT), and reduced glutathione (GSH)], and oxidant biomarker malondialdehyde (MDA) were examined via ELISA. Meanwhile, inflammatory cytokine (IL-6 and TNF-α) levels, and key molecules (NF-κB p65), cyclooxygenase 1 (COX-1 and COX2) involved in NF-κB pathway, were analyzed by using Western Blot. COX-1 and COX-2 levels were further measured by immunohistochemistry. The effects of DNJ on gastric functions were explored by measuring the changes of Motilin (MOT), Substance P (SP), Somatostatin (SS), and Vasoactive intestinal peptide (VIP) in GU mouse models with ELISA Kits. The results indicated that DNJ prevented indomethacin-caused increase of gastric volume. DNJ improved histopathology of GU mice when compared with the mice from IG group (P < 0.05). DNJ consumption decreased the levels of IL-6 and TNF-α (P < 0.05). DNJ increased antioxidant indices of GU mice by improving the activities of SOD, CAT and reduced GSH, and reduced MDA levels (P < 0.05). DNJ increased the levels of prostaglandin E2, COX-1, COX2, and reduced the levels of and NF-κB p65 (P < 0.05). DNJ showed protection for gastric functions of GU mice by reducing the levels of MOT and SP, and increasing the levels of SS and VIP. DNJ treatment inactivates NF-κB signaling pathway, and increases anti-ulceration ability of the models. Frontiers Media S.A. 2018-04-19 /pmc/articles/PMC5917448/ /pubmed/29725297 http://dx.doi.org/10.3389/fphar.2018.00372 Text en Copyright © 2018 Piao, Li, Sui, Guo, Liu, Li, Gao, Cai, Li, Wang and Liu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Piao, Xuehua
Li, Shuangdi
Sui, Xiaodan
Guo, Lianyi
Liu, Xingmei
Li, Hongmei
Gao, Leming
Cai, Shusheng
Li, Yanrong
Wang, Tingting
Liu, Baohai
1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway
title 1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway
title_full 1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway
title_fullStr 1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway
title_full_unstemmed 1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway
title_short 1-Deoxynojirimycin (DNJ) Ameliorates Indomethacin-Induced Gastric Ulcer in Mice by Affecting NF-kappaB Signaling Pathway
title_sort 1-deoxynojirimycin (dnj) ameliorates indomethacin-induced gastric ulcer in mice by affecting nf-kappab signaling pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917448/
https://www.ncbi.nlm.nih.gov/pubmed/29725297
http://dx.doi.org/10.3389/fphar.2018.00372
work_keys_str_mv AT piaoxuehua 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway
AT lishuangdi 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway
AT suixiaodan 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway
AT guolianyi 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway
AT liuxingmei 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway
AT lihongmei 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway
AT gaoleming 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway
AT caishusheng 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway
AT liyanrong 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway
AT wangtingting 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway
AT liubaohai 1deoxynojirimycindnjamelioratesindomethacininducedgastriculcerinmicebyaffectingnfkappabsignalingpathway